EUVIMEDEUVIMED entdecken
Open Access

High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study

Shelley Perkins, Sophie Krahnke, Erik K Larsen, Matthew Drew, Peter H Frank, Min Hong, Dana Rabara, Vanessa E Wall, Carissa Grose, William Gillette, Dominic Esposito, Andrew G Stephen und 1 weitere

Protein Expression and Purification · 2026-09 · 242 · 106950

DOI: 10.1016/j.pep.2026.106950 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein Expression and Purification, 2026-09. Verfasst von Shelley Perkins und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Re…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Membrane Proteins, GTP Phosphohydrolases, Oncogene Protein p21(ras). Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Cancer Institute Frederick National Laboratory for Cancer Research, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The classical RAS family of proteins consist of four isoforms HRAS, KRAS4a, KRAS4b, and NRAS, mutations in which lead to several types of human cancer, including pancreatic, colorectal, lung, and melanoma. RAS proteins function as molecular switches in the cell that control cell growth and proliferation. Two critical elements for RAS activation are loading of a molecule of GTP and localization to the plasma membrane. This last element is facilitated by the post-translational modification of the C-terminus, where three C-terminal residues are cleaved, and a cysteine is both farnesylated and methylated to generate a hydrophobic lipid tail that can insert into the membrane. Using an insect cell expression platform previously used to produce post-translationally modified KRAS4b, we describe a protocol here that leads to milligram quantities of protein for HRAS, KRAS4a, and NRAS targets. We also show that these proteins can bind the RAS binding domain of RAF1 and bind lipid nanodiscs. Production of these three post-translationally modified proteins is important for future novel drug-screening campaigns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Membrane ProteinsGTP PhosphohydrolasesOncogene Protein p21(ras)HumansAnimalsProtein Processing, Post-TranslationalProto-Oncogene Proteins c-rafRecombinant ProteinsProtein BindingSf9 Cells

Stichwörter der Autor:innen

FarnesylationHRASKRAS4aMethylationNRASRat Sarcoma Virus protein (RAS)

Substanzen

Proto-Oncogene Proteins p21(ras)Membrane ProteinsNRAS protein, humanGTP PhosphohydrolasesHRAS protein, humanProto-Oncogene Proteins c-rafRaf1 protein, humanRecombinant ProteinsOncogene Protein p21(ras)

Autor:innen und Institutionen

  • National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, 21702, USA.
  • National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, 21702, USA. Electronic address: simon.mes…

Förderung

  • NIH HHS
  • National Cancer Institute Frederick National Laboratory for Cancer Research
  • National Institutes of Health
  • National Cancer Institute
  • U.S. Department of Health and Human Services

Zitieren

APA

Perkins, S., Krahnke, S., Larsen, E. K., Drew, M., Frank, P. H., Hong, M., Rabara, D., Wall, V. E., Grose, C., Gillette, W., Esposito, D., Stephen, A. G., & Messing, S. A. (2026). High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study. Protein Expression and Purification, 242, 106950. https://doi.org/10.1016/j.pep.2026.106950

Vancouver

Perkins S, Krahnke S, Larsen EK, Drew M, Frank PH, Hong M, et al. High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study. Protein Expression and Purification. 2026;242:106950. doi:10.1016/j.pep.2026.106950

BibTeX
@article{Perkins2026,
  author = {Perkins, Shelley and Krahnke, Sophie and Larsen, Erik K and Drew, Matthew and Frank, Peter H and Hong, Min and Rabara, Dana and Wall, Vanessa E and Grose, Carissa and Gillette, William and Esposito, Dominic and Stephen, Andrew G and Messing, Simon A},
  title = {High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study},
  journal = {Protein Expression and Purification},
  year = {2026},
  volume = {242},
  pages = {106950},
  doi = {10.1016/j.pep.2026.106950}
}
Kostenlos starten →